Abstract 2056: Cross-species microRNA expression patterns identify potential therapeutic targets in osteosarcoma.

Abstract Osteosarcoma is the most common primary bone tumour in both humans and dogs. In both species, osteosarcoma displays a marked propensity for pulmonary metastasis, making canines a robust and clinically relevant translational model of the disease. With current standard-of-care treatment, the 5-year survival rate for humans with localized osteosarcoma is approximately 60-70%, but falls to around 20-30% for patients presenting with metastatic disease. In dogs, amputation followed by chemotherapy yields a median survival time of roughly 10-12 months, with fewer than 20% surviving beyond two years. Despite incremental improvements in supportive care, therapeutic strategies for osteosarcoma have remained largely unchanged for more than three decades in both species, highlighting the need for novel prognostic indicators and therapeutic targets. MicroRNAs (miRNAs) are small, non-coding RNAs that can function as tumour suppressors or oncogenes. They are expressed across diverse tissues and are known to exhibit dysregulation in cancer. In this study, 20 osteosarcoma cell lines (6 human and 14 canine), derived from both primary and metastatic tumours, were evaluated for key malignant behaviours using a series of in vitro functional assays. These included measurements of proliferation (doubling time), migration (scratch and transwell assays), anchorage-independent survival (anoikis assay), invasion (drop invasion assay), and colony formation (clonogenic assay). RNA was subsequently isolated from each cell line, and expression of 48 candidate miRNAs was quantified using real-time quantitative polymerase chain reaction (RT-qPCR). Each miRNA was correlated with measured behaviours using Pearson’s r and false discovery rate (FDR) analysis. Ten miRNAs were significantly associated with at least one behaviour at p < 0.05 following FDR correction. Notably, miR-708-5p demonstrated significant correlations with multiple malignant phenotypes, including doubling time, migration, and colony formation. MiRNA expression profiles, therefore, revealed several candidates associated with malignant behaviour, suggesting that select miRNAs may contribute to disease progression and represent promising targets for future therapeutic development. Citation Format: Sophia C. Fernandes, Emma N. Vanderboon, Alicia Viloria-Petit, R. Darren Wood, Geoffrey A. Wood. Cross-species microRNA expression patterns identify potential therapeutic targets in osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2056.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-2056
Primary Topic
Veterinary Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 2056: Cross-species microRNA expression patterns identify potential therapeutic targets in osteosarcoma.

Geoffrey A. Wood, Emma N. Vanderboon, Alicia Viloria-Petit, R. Darren Wood et al.
Cancer Research
Veterinary Oncology Research
article

Abstract 2056: Cross-species microRNA expression patterns identify potential therapeutic targets in osteosarcoma.

Geoffrey A. Wood, Emma N. Vanderboon, Alicia Viloria-Petit, R. Darren Wood, Sophia C. Fernandes
article en

Abstract

Abstract Osteosarcoma is the most common primary bone tumour in both humans and dogs. In both species, osteosarcoma displays a marked propensity for pulmonary metastasis, making canines a robust and clinically relevant translational model of the disease. With current standard-of-care treatment, the 5-year survival rate for humans with localized osteosarcoma is approximately 60-70%, but falls to around 20-30% for patients presenting with metastatic disease. In dogs, amputation followed by chemotherapy yields a median survival time of roughly 10-12 months, with fewer than 20% surviving beyond two years. Despite incremental improvements in supportive care, therapeutic strategies for osteosarcoma have remained largely unchanged for more than three decades in both species, highlighting the need for novel prognostic indicators and therapeutic targets. MicroRNAs (miRNAs) are small, non-coding RNAs that can function as tumour suppressors or oncogenes. They are expressed across diverse tissues and are known to exhibit dysregulation in cancer. In this study, 20 osteosarcoma cell lines (6 human and 14 canine), derived from both primary and metastatic tumours, were evaluated for key malignant behaviours using a series of in vitro functional assays. These included measurements of proliferation (doubling time), migration (scratch and transwell assays), anchorage-independent survival (anoikis assay), invasion (drop invasion assay), and colony formation (clonogenic assay). RNA was subsequently isolated from each cell line, and expression of 48 candidate miRNAs was quantified using real-time quantitative polymerase chain reaction (RT-qPCR). Each miRNA was correlated with measured behaviours using Pearson’s r and false discovery rate (FDR) analysis. Ten miRNAs were significantly associated with at least one behaviour at p < 0.05 following FDR correction. Notably, miR-708-5p demonstrated significant correlations with multiple malignant phenotypes, including doubling time, migration, and colony formation. MiRNA expression profiles, therefore, revealed several candidates associated with malignant behaviour, suggesting that select miRNAs may contribute to disease progression and represent promising targets for future therapeutic development. Citation Format: Sophia C. Fernandes, Emma N. Vanderboon, Alicia Viloria-Petit, R. Darren Wood, Geoffrey A. Wood. Cross-species microRNA expression patterns identify potential therapeutic targets in osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2056.

Cancer ResearchVol. 86(7_Supplement)
University of Guelph (CA)
Openalex Percentile: Top 5%
Veterinary Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.